metaEvidence - overview

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1) 2
mCRC - 2nd line (L2) 3
endometrial cancer 10

immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
Immune checkpoint association
durvalumab plus tremelimumab

versus all
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs regorafenib

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

button bars forest bayes pooled summary circles


			PFS (extension)
mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open